Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • hollystephens723
    Member
    • Dec 2018
    • 36

    #1

    Deadline extended for the FDA Open Data Adverse Event Anomalies Challenge

    In response to a flurry of new interest in the Gaining New Insights by Detecting Adverse Event Anomalies Using FDA Open Data Challenge we have decided to extend the submission period to March 13th. New guidance is available on the challenge site including updated evaluation criteria and anomaly examples.

    Please also note that providing code is no longer required for a valid final submission. Selected contributors will be invited to participate in a panel at the Modernizing FDA’s Data Strategy public meeting. We are also pleased to announce that the Journal of the American Medical Informatics Association (JAMIA) supports the submission of a paper describing the challenge and the insights that emerge from it.

    If you are interested in learning more about how FDA is modernizing its data strategy, please attend the Modernizing FDA’s Data Strategy public meeting on March 27th. The meeting will also be streamed virtually for those who don’t live in the DC area!

    If you have any questions about the challenge, please feel free to post them in this thread and we will respond as quickly as possible.

Latest Articles

Collapse

  • SEQadmin2
    16S/ITS Profiling vs. Shotgun Metagenomics: What Changes in Your Workflow?
    by SEQadmin2




    NGS has revolutionized clinical microbiology by offering new ways to identify and surveil pathogens without prior knowledge of the target. One popular approach is 16S rRNA and ITS amplicon sequencing, which targets specific microbial markers. But studies are increasingly incorporating shotgun metagenomics, a technique that sequences all DNA from a sample without targeting specific microbial markers. This approach allows more detailed taxonomic classification, detection...
    Yesterday, 06:46 AM
  • SEQadmin2
    Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
    by SEQadmin2



    Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

    Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
    ...
    10-14-2026, 09:55 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, 10-28-2026, 09:57 AM
0 responses
26 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-28-2026, 09:51 AM
0 responses
17 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-22-2026, 11:13 AM
0 responses
71 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-22-2026, 10:48 AM
0 responses
48 views
0 reactions
Last Post SEQadmin2  
Working...